A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...

HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies ...

From mixed to matched: New marker pinpoints therapeutically relevant stem cell-derived islets by The Lundquist Institute edited by Sadie Harley, reviewed by Robert Egan Editors' notes ...

From mixed to matched: new marker pinpoints therapeutically relevant stem cell–derived islets Human pluripotent stem cell–derived islets hold great promise as a functional cure for diabetes.

Marker Therapeutics, Inc. has announced a collaboration with Cellipont Bioservices to support the cGMP manufacturing of MT-601, its lead Multi-Antigen Recognizing (MAR)-T cell therapy, currently ...

Marker Therapeutics, Inc. is a Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of ...

A new study reveals that blocking ribosomal RNA production rewires cancer cell behavior and could help treat genetically ...

Our study addresses this challenge by resolving the heterogeneity of human stem cell–derived islet organoids and introducing a functional marker to isolate transplant-ready islets," said Dr ...

However, the lack of reliable markers to identify truly functional, stem cell–derived islets has hindered the consistent production needed for clinical application.